MX2015005632A - Sales de amina de laquinimod. - Google Patents
Sales de amina de laquinimod.Info
- Publication number
- MX2015005632A MX2015005632A MX2015005632A MX2015005632A MX2015005632A MX 2015005632 A MX2015005632 A MX 2015005632A MX 2015005632 A MX2015005632 A MX 2015005632A MX 2015005632 A MX2015005632 A MX 2015005632A MX 2015005632 A MX2015005632 A MX 2015005632A
- Authority
- MX
- Mexico
- Prior art keywords
- laquinimod
- amine salts
- lysine
- meglumine
- monoethanolamine
- Prior art date
Links
- 229960004577 laquinimod Drugs 0.000 title abstract 6
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical class OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title abstract 5
- -1 Amine salts Chemical class 0.000 title abstract 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 2
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 abstract 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 abstract 1
- 235000019766 L-Lysine Nutrition 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 abstract 1
- 229940075419 choline hydroxide Drugs 0.000 abstract 1
- 229960003194 meglumine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Epidemiology (AREA)
- Electric Double-Layer Capacitors Or The Like (AREA)
- Cosmetics (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723495P | 2012-11-07 | 2012-11-07 | |
| PCT/US2013/067686 WO2014074381A1 (en) | 2012-11-07 | 2013-10-31 | Amine salts of laquinimod |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015005632A true MX2015005632A (es) | 2016-02-05 |
Family
ID=50622908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015005632A MX2015005632A (es) | 2012-11-07 | 2013-10-31 | Sales de amina de laquinimod. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8975279B2 (enExample) |
| EP (1) | EP2916915A4 (enExample) |
| JP (1) | JP2015535287A (enExample) |
| KR (1) | KR20150091077A (enExample) |
| CN (1) | CN104955522A (enExample) |
| AR (1) | AR093335A1 (enExample) |
| AU (1) | AU2013341506A1 (enExample) |
| BR (1) | BR112015010193A2 (enExample) |
| CA (1) | CA2890194A1 (enExample) |
| EA (1) | EA201590788A1 (enExample) |
| HK (2) | HK1215210A1 (enExample) |
| IL (1) | IL238535A0 (enExample) |
| MX (1) | MX2015005632A (enExample) |
| TW (1) | TW201422588A (enExample) |
| WO (1) | WO2014074381A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015505564A (ja) | 2012-02-03 | 2015-02-23 | テバ ファーマシューティカル インダストリーズ リミティド | 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用 |
| JP6215238B2 (ja) | 2012-02-16 | 2017-10-18 | テバ ファーマシューティカル インダストリーズ リミティド | Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| ES3014202T3 (en) | 2014-03-26 | 2025-04-21 | Astex Therapeutics Ltd | Cmet-inhibitors for use in delaying the emergence in resistance to fgfr inhibitors |
| AU2015253330A1 (en) | 2014-04-29 | 2016-12-01 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US20180071376A1 (en) | 2015-03-23 | 2018-03-15 | The Brigham And Women`S Hospital, Inc. | Tolerogenic nanoparticles for treating diabetes mellitus |
| EP3829557A1 (en) | 2018-08-03 | 2021-06-09 | Institut National De La Sante Et De La Recherche Medicale - Inserm | Biocompatible tolerogenic nanoparticles |
| EP3886893A1 (en) | 2018-11-27 | 2021-10-06 | Institut National De La Sante Et De La Recherche Medicale - Inserm | Nanoparticles for preparing regulatory b cells |
| KR20210124855A (ko) | 2020-04-07 | 2021-10-15 | 주식회사 엘에스파마 | 고미가 차폐된 디클로페낙을 함유하는 약제학적 조성물 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3024257A (en) | 1961-04-10 | 1962-03-06 | Frosst & Co Charles E | Stable preparations of alkali metal salts of estrone sulfate |
| FR2340735A1 (fr) | 1976-02-11 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
| IE52670B1 (en) | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| DE3437232A1 (de) | 1984-10-10 | 1986-04-17 | Mack Chem Pharm | Stabilisierte injektionsloesungen von piroxicam |
| US4782155A (en) | 1986-03-19 | 1988-11-01 | Banyu Pharmaceutical Co., Ltd. | Cephalosporin derivatives, processes for their preparation and antibacterial agents |
| SE8902076D0 (sv) | 1989-06-09 | 1989-06-09 | Pharmacia Ab | Derivatives of quinoline-3-carboxanilide |
| HUT60458A (en) | 1991-02-01 | 1992-09-28 | Sandoz Ag | Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same |
| US5139878A (en) | 1991-08-12 | 1992-08-18 | Allied-Signal Inc. | Multilayer film constructions |
| US5540934A (en) | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
| CH687615A5 (de) | 1994-09-07 | 1997-01-15 | R W Johnson Pharmaceutical Res | Tropen-Verpackung. |
| US5912349A (en) | 1997-01-31 | 1999-06-15 | Pharmacia & Upjohn Company | Process for the preparation of roquinimex |
| US20030124187A1 (en) | 1997-02-14 | 2003-07-03 | Smithkline Beecham Laboratoires Pharmaceutiques, | Pharmaceutical formulations comprising amoxycillin and clavulanate |
| US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| US6133285A (en) | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
| US6121287A (en) | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
| SI1187601T1 (sl) | 1999-06-07 | 2005-12-31 | Altana Pharma Ag | Novi pripravek in dajalna oblika, ki obsega kislinsko labilen inhibitor protonske crpalke |
| CN100390148C (zh) | 1999-10-25 | 2008-05-28 | 活跃生物技术有限公司 | 用于治疗恶性肿瘤的药物 |
| SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| JP2002031610A (ja) | 2000-07-14 | 2002-01-31 | Ajinomoto Co Inc | 生体分子複合体の界面残基を同定する方法 |
| US6307050B1 (en) | 2000-08-29 | 2001-10-23 | R. T. Alamo Venture I Llc | Method of synthesizing flosequinan from 4-fluoroanthranilic acid |
| US6802422B2 (en) | 2000-12-12 | 2004-10-12 | Multi-Comp, Inc. | Sealed blister assembly |
| US6706733B2 (en) | 2001-05-08 | 2004-03-16 | Dainippon Ink And Chemicals, Inc. | Quinolinone derivative formulation and its production method |
| US20030119826A1 (en) | 2001-09-24 | 2003-06-26 | Pharmacia Corporation | Neuroprotective treatment methods using selective iNOS inhibitors |
| US7560557B2 (en) | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| ITMI20021726A1 (it) | 2002-08-01 | 2004-02-02 | Zambon Spa | Macrolidi ad attivita' antiinfiammatoria. |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| US20040253305A1 (en) | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
| AU2003300692A1 (en) | 2003-10-30 | 2005-05-19 | Lupin Ltd. | Stable formulations of ace inhibitors and methods for preparation thereof |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| PL1902034T3 (pl) | 2005-06-02 | 2011-09-30 | Glenmark Pharmaceuticals Sa | Nowe ligandy receptorów kanabinoidowych, kompozycja farmaceutyczna je zawierająca oraz proces ich wytwarzania |
| KR101440982B1 (ko) | 2005-10-19 | 2014-09-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 나트륨의 결정 및 이의 제조방법 |
| BRPI0708902A2 (pt) | 2006-03-16 | 2011-06-14 | Genentech Inc | mÉtodos de tratar lupus usando anticorpos cd4 |
| US7989473B2 (en) * | 2006-06-12 | 2011-08-02 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| SI2056807T1 (sl) | 2006-08-17 | 2012-12-31 | University Of Chicago | Zdravljenje vnetnih bolezni |
| EP2214657A1 (en) | 2007-10-23 | 2010-08-11 | UCB Pharma GmbH | Compounds for treating demyelination conditions |
| US8178127B2 (en) * | 2007-12-20 | 2012-05-15 | Teva Pharmaceuticals Industries, Ltd. | Stable laquinimod preparations |
| US8354428B2 (en) | 2008-07-01 | 2013-01-15 | Actavis Group Ptc Ehf | Solid state forms of laquinimod and its sodium salt |
| JP2012502038A (ja) | 2008-09-03 | 2012-01-26 | テバ ファーマシューティカル インダストリーズ リミティド | 免疫機能の２−オキソ−１，２−ジヒドロ−キノリンモジュレーター |
| TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
| UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
| US20100260755A1 (en) | 2009-04-09 | 2010-10-14 | Medicinova, Inc. | Ibudilast and immunomodulators combination |
| DK2442651T3 (en) | 2009-06-19 | 2015-09-21 | Teva Pharma | Treatment of multiple sclerosis with laquinimod |
| MX2012001333A (es) | 2009-07-30 | 2012-06-01 | Teva Pharma | Tratamiento de la enfermedad de crohn con la laquinimod. |
| PT2467372T (pt) | 2009-08-10 | 2016-08-23 | Teva Pharma | Tratamento de distúrbios relacionados com bdnf usando laquinimod |
| US20130035390A1 (en) * | 2010-01-13 | 2013-02-07 | Ramot At Tel-Aviv University Ltd. | Treatment of multiple sclerosis |
| AU2011223702B2 (en) | 2010-03-03 | 2016-07-14 | Teva Pharmaceutical Industries Ltd. | Treatment of lupus arthritis using laquinimod |
| SG183513A1 (en) | 2010-03-03 | 2012-09-27 | Teva Pharma | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
| EP2590653A4 (en) | 2010-07-09 | 2014-01-01 | Teva Pharma | 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF |
| CN104610144A (zh) | 2010-07-09 | 2015-05-13 | 泰华制药工业有限公司 | 氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途 |
| EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| SG10201509831XA (en) | 2010-12-07 | 2015-12-30 | Teva Pharma | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
| EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| IN2014MN00333A (enExample) | 2011-07-28 | 2015-09-25 | Teva Pharma | |
| JP2014521659A (ja) | 2011-07-28 | 2014-08-28 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療 |
| EP2766020A4 (en) | 2011-10-12 | 2015-04-01 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD |
| JP2015505564A (ja) | 2012-02-03 | 2015-02-23 | テバ ファーマシューティカル インダストリーズ リミティド | 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用 |
| JP6215238B2 (ja) | 2012-02-16 | 2017-10-18 | テバ ファーマシューティカル インダストリーズ リミティド | Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用 |
| US20130259856A1 (en) | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| AR090885A1 (es) | 2012-05-02 | 2014-12-10 | Teva Pharma | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| US20130345257A1 (en) | 2012-06-26 | 2013-12-26 | The Regents Of The University Of California | Composition for lupus nephritis and methods of making and using the same |
| AR091706A1 (es) | 2012-07-11 | 2015-02-25 | Teva Pharma | Formulaciones de laquinimod sin agentes alcalinizantes |
| UY34896A (es) | 2012-07-12 | 2014-02-28 | Teva Pharma | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina |
| TW201410243A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
-
2013
- 2013-10-31 HK HK16103249.5A patent/HK1215210A1/zh unknown
- 2013-10-31 WO PCT/US2013/067686 patent/WO2014074381A1/en not_active Ceased
- 2013-10-31 KR KR1020157014911A patent/KR20150091077A/ko not_active Withdrawn
- 2013-10-31 AU AU2013341506A patent/AU2013341506A1/en not_active Abandoned
- 2013-10-31 HK HK16100794.0A patent/HK1212936A1/zh unknown
- 2013-10-31 US US14/068,599 patent/US8975279B2/en not_active Expired - Fee Related
- 2013-10-31 JP JP2015540779A patent/JP2015535287A/ja active Pending
- 2013-10-31 EA EA201590788A patent/EA201590788A1/ru unknown
- 2013-10-31 CA CA2890194A patent/CA2890194A1/en not_active Abandoned
- 2013-10-31 CN CN201380058339.0A patent/CN104955522A/zh active Pending
- 2013-10-31 EP EP13852663.7A patent/EP2916915A4/en not_active Withdrawn
- 2013-10-31 BR BR112015010193A patent/BR112015010193A2/pt active Search and Examination
- 2013-10-31 MX MX2015005632A patent/MX2015005632A/es unknown
- 2013-11-01 AR ARP130104013A patent/AR093335A1/es unknown
- 2013-11-05 TW TW102140149A patent/TW201422588A/zh unknown
-
2015
- 2015-04-30 IL IL238535A patent/IL238535A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201422588A (zh) | 2014-06-16 |
| HK1215210A1 (zh) | 2016-08-19 |
| US8975279B2 (en) | 2015-03-10 |
| US20140128430A1 (en) | 2014-05-08 |
| BR112015010193A2 (pt) | 2017-07-11 |
| JP2015535287A (ja) | 2015-12-10 |
| EP2916915A1 (en) | 2015-09-16 |
| WO2014074381A1 (en) | 2014-05-15 |
| AU2013341506A1 (en) | 2015-06-04 |
| KR20150091077A (ko) | 2015-08-07 |
| CA2890194A1 (en) | 2014-05-15 |
| CN104955522A (zh) | 2015-09-30 |
| HK1212936A1 (zh) | 2016-06-24 |
| EA201590788A1 (ru) | 2015-12-30 |
| AR093335A1 (es) | 2015-06-03 |
| EP2916915A4 (en) | 2016-06-22 |
| IL238535A0 (en) | 2015-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015005632A (es) | Sales de amina de laquinimod. | |
| IL242278A0 (en) | Compounds 4)-n-fluoro-2-methoxy-5-nitrophenyl)pyrimidine-2-converted amine and their salts | |
| PH12015502031A1 (en) | Tetrahydropyrrolothiazine compounds | |
| EA201591634A1 (ru) | Дигидропиридопиримидиновые соединения | |
| DK2915804T3 (da) | Nyt aminderivat eller salt deraf som TNF-alpha-inhibitorer | |
| CR20140306A (es) | Fluormetil -5,6-dihidro-4h-[1,3] oxazinas | |
| PH12017501523A1 (en) | Selective bace1 inhibitors | |
| BR112013007821A2 (pt) | método para a preparação de uma composição de concentrado aquoso de glifosato contendo mistura de sais de amina | |
| EA201590018A1 (ru) | Способ и промежуточные соединения для получения ингибиторов интегразы | |
| PH12016502229A1 (en) | Process for preparing phosphorus-containing cyanohydrins | |
| MX2016010973A (es) | Compuestos de aminocarbonilcarbamato. | |
| CR20140495A (es) | 5-amino[1,4]thiazines como inhibidores de bace1 | |
| MY183123A (en) | Synthesis of copanlisib and its di hydrochloride salt | |
| IN2014DN07996A (enExample) | ||
| UY34553A (es) | Procedimiento de preparación de la sal de l-arginina de perindoprilo | |
| IN2014DN06192A (enExample) | ||
| BR112018012325A2 (pt) | métodos para a preparação de 5,6-di-hidro-6-fenilbenzo[f]isoquinolin-2-amina substituída | |
| MX2015005739A (es) | Compuestos novedosos de bencil sulfonamida utiles como inhibidores de mogat-2. | |
| EA201690593A1 (ru) | Новые соединения мочевины | |
| IN2013MU01501A (enExample) | ||
| GB201611609D0 (en) | Valsartan amine salts | |
| GB201611608D0 (en) | Valsartan amine salts | |
| UA94667U (uk) | Заміщені [2-(3-r-1h-[1,2,4]триазол-5-іл)феніл]аміни, що проявляють гіпоглікемічну активність | |
| UA86566U (en) | N-hydroxyhomoazaadamantanone and dioxomolybdenum complex thereof | |
| GB201611641D0 (en) | Iosartan amine salts |